Citigroup Maintains Neutral on Zimmer Biomet Holdings, Lowers Price Target to $93

Benzinga Newsdesk www.benzinga.com Negative 63.7%

Neg 63.7% Neu 0% Pos 0%

Citigroup analyst Joanne Wuensch maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Neutral and lowers the price target from $95 to $93.